Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Company profile
Ticker
MGTA
Exchange
Website
CEO
Jason Gardner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Magenta Securities Corporation ...
MGTA stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
23 Mar 23
8-K
Results of Operations and Financial Condition
7 Feb 23
8-K
Magenta Therapeutics to Explore Strategic Alternatives
2 Feb 23
8-K
Regulation FD Disclosure
25 Jan 23
8-K
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
20 Dec 22
8-K
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
13 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Magenta Therapeutics Reports Third Quarter Financial Results
3 Nov 22
424B5
Prospectus supplement for primary offering
18 Aug 22
8-K
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
17 Aug 22
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Aquilo Capital Management, LLC
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13G/A
GILDER GAGNON HOWE & CO LLC
14 Feb 23
SC 13G/A
Casdin Capital, LLC
13 Feb 23
SC 13G
TANG CAPITAL PARTNERS LP
13 Feb 23
4
Change in insider ownership
9 Feb 23
4
Thomas W. Beetham
2 Dec 22
4
Stephen F. Mahoney
2 Dec 22
4
Caren Deardorf
2 Dec 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm |
| Cash burn (monthly) | 467.33 k | 6.17 mm | 7.24 mm | 6.74 mm | 5.56 mm | 5.59 mm |
| Cash used (since last report) | 1.39 mm | 18.39 mm | 21.60 mm | 20.10 mm | 16.58 mm | 16.67 mm |
| Cash remaining | 58.01 mm | 41.01 mm | 37.81 mm | 39.31 mm | 42.82 mm | 42.74 mm |
| Runway (months of cash) | 124.1 | 6.6 | 5.2 | 5.8 | 7.7 | 7.6 |
Institutional ownership, Q2 2022
9.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 75 |
| Opened positions | 15 |
| Closed positions | 32 |
| Increased positions | 19 |
| Reduced positions | 20 |
| 13F shares | Current |
|---|---|
| Total value | 145.65 mm |
| Total shares | 51.83 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| TRV GP Iv | 6.76 mm | $8.11 mm |
| Third Rock Ventures IV | 6.76 mm | $29.94 mm |
| Deep Track Capital | 5.36 mm | $6.43 mm |
| Atlas Venture Life Science Advisors | 3.48 mm | $4.17 mm |
| JHG Janus Henderson | 3.00 mm | $3.57 mm |
| Atlas Venture Fund X | 2.98 mm | $31.86 mm |
| Casdin Capital | 2.42 mm | $2.90 mm |
| Orbimed Advisors | 2.25 mm | $2.70 mm |
| TCG Crossover Management | 2.12 mm | $2.55 mm |
| Vanguard | 1.91 mm | $2.29 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Feb 23 | Third Rock Ventures IV | Common Stock | Sell | Dispose S | No | No | 0.82 | 1,500,000 | 1.23 mm | 3,058,204 |
| 7 Feb 23 | Third Rock Ventures IV | Common Stock | Sell | Dispose S | No | No | 0.83 | 2,200,000 | 1.83 mm | 4,558,204 |
| 30 Nov 22 | Kristen Stants | Common Stock | Grant | Acquire A | No | No | 0.94 | 3,000 | 2.82 k | 20,264 |
| 30 Nov 22 | Stephen F. Mahoney | Common Stock | Grant | Acquire A | No | No | 0.94 | 3,000 | 2.82 k | 17,264 |
| 30 Nov 22 | Caren Deardorf | Common Stock | Grant | Acquire A | No | No | 0.94 | 3,000 | 2.82 k | 19,762 |
| 30 Nov 22 | Jason Gardner | Common Stock | Grant | Acquire A | No | No | 0.94 | 3,000 | 2.82 k | 292,872 |
News
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
28 Feb 23
HC Wainwright & Co. Initiates Coverage On Magenta Therapeutics with Neutral Rating
28 Feb 23
Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms
9 Feb 23
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
8 Feb 23
12 Health Care Stocks Moving In Friday's Intraday Session
3 Feb 23
Press releases
Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai?
3 Feb 23
Magenta Therapeutics to Explore Strategic Alternatives
2 Feb 23
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
25 Jan 23